drug_type
RELEVANT_DRUG
intervention_type
Biologic (humanized monoclonal antibody)
drug_description
Humanized anti-EpCAM monoclonal antibody administered by weekly IV infusion (0.1–15 mg/kg) in dose escalation for advanced solid tumors; binds EpCAM on tumor cells to inhibit EpCAM-mediated adhesion/signaling and engage Fc-dependent immune cytotoxicity (e.g., ADCC/CDC).
nci_thesaurus_concept_id
C200195
nci_thesaurus_definition
A humanized monoclonal antibody directed against the tumor-associated antigen (TAA) epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antineoplastic activity. Upon administration, anti-EpCAM monoclonal antibody AM-928 targets and binds to EpCAM on EpCAM-expressing tumor cells. This inhibits EpCAM-mediated signaling and the proliferation of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.
drug_mesh_term
Antibodies, Monoclonal, Humanized
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody that binds EpCAM (CD326) on tumor cells, blocks EpCAM-mediated adhesion/signaling, and triggers Fc-dependent immune effector functions (ADCC/CDC) to kill EpCAM-positive cancer cells.
drug_name
AM-928
nct_id_drug_ref
NCT05687682